[To what extent can prostaglandin synthesis inhibitors of the non-steroidal antirheumatic (NSAR) type modify the effect of ACE inhibitors?].
Grote
L
L
Medizinische Poliklinik, Klinikum, Phillips-Universität, Marburg.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D000075202:Contraindications; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007677:Kidney Function Tests; D012084:Renin-Angiotensin System / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000959:Antihypertensive Agents
In welchem Ausmass können Prostaglandinsynthesehemmer vom Typ der nichtsteroidalen Antirheumatika (NSAR) die Wirkung von ACE-Hemmern beeinflussen?